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Abstract
Background: Periodontal disease (PD) is an infectious clinical entity characterized by the destruction of supporting
tissues of the teeth as the result of a chronic inflammatory response in a susceptible host. It has been proposed
that PD as subclinical infection may contribute to the etiology and to the pathogenesis of several systemic
diseases including Atherosclerosis. A number of epidemiological studies link periodontal disease/edentulism as
independent risk factor for acute myocardial infarction, peripheral vascular disease, and cerebrovascular disease.
Moreover, new randomized controlled clinical trials have shown an improvement on cardiovascular surrogate
markers (endothelial function, sICAM, hsPCR level, fibrinogen) after periodontal treatment. Nonetheless, such trials
are still limited in terms of external validity, periodontal treatment strategies, CONSORT-based design and results
consistency/extrapolation. The current study is designed to evaluate if periodontal treatment with scaling and root
planning plus local delivered chlorhexidine improves endothelial function and other biomarkers of cardiovascular
disease in subjects with moderate to severe periodontitis.
Methods/Design: This randomized, single-blind clinical trial will be performed at two health centers and will
include two periodontal treatment strategies. After medical/periodontal screening, a baseline endothelium-
dependent brachial artery flow-mediated dilatation (FMD) and other systemic surrogate markers will be obtained
from all recruited subjects. Patients then will be randomized to receive either supragingival/subgingival plaque
cleaning and calculus removal plus chlorhexidine (treatment group) or supragingival plaque removal only (control
group). A second and third FMD will be obtained after 24 hours and 12 weeks in both treatment arms. Each group
will consist of 49 patients (n = 98) and all patients will be followed-up for secondary outcomes and will be
monitored through a coordinating center. The primary outcomes are FMD differences baseline, 24 hours and 3
months after treatment. The secondary outcomes are differences in C-reactive protein (hs-CRP), glucose serum
levels, blood lipid profile, and HOMA index.
Discussion: This RCT is expected to provide more evidence on the effects of different periodontal treatment
modalities on FMD values, as well as to correlate such findings with different surrogate markers of systemic
inflammation with cardiovascular effects.
Trial registration number: ClinicalTrials.gov Identifier: NCT00681564.
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Cardiovascular disease continues to be the main cause
of morbidity and mortality worldwide. Despite the exis-
tence of novel therapeutic approaches designed for the
prevention and treatment of atherosclerosis, the number
of deaths associated to cardiovascular events remains
constant in most countries [1]. For instance, in Colom-
bia, one out of five deaths can be attributed to ischemic
cardiovascular disease[2]. During the last decade it has
been widely accepted that inflammation plays a key role
in the development of atherosclerosis. Multiple epide-
miological studies have confirmed the association
between high levels of acute phase reactants such as
C-reactive protein (CRP), fibrinogen, Serum Amyloid A
and soluble adhesion molecules like ICAM-1, E-Selectin,
VCAM-1 with the progression of atherosclerosis and
also with an increased risk for cardiovascular disease [3].
New scientific evidence from the last two decades
including epidemiological, in vivo and in vitro assays
supports the notion that the immune system signifi-
cantly contributes in the development and progression
of atherosclerosis [4]. This new theory proposes that
any potential noxious challenge to the host immune
response could be related to the pathogenesis of athero-
sclerosis [5]. Hence, other nontraditional risk factors for
cardiovascular events, such as infections and rheumato-
logic autoimmune diseases have emerged as important
risk factors [6].
Several epidemiological studies have also suggested
that periodontal infection is an independent risk factor
for acute myocardial infarction, peripheral vascular dis-
ease and cerebrovascular disease. A recent meta-analysis
on the subset of five cohort studies (86,092 patients, fol-
low-up > 6 years) found increased incidence of coronary
heart disease (RR = 1.24, 95% CI 1.14-1.36, p < .0001) in
patients with less than 10 teeth. In the subset of cross-
sectional studies at the same meta-analysis report,
prevalence of coronary heart disease was reported to be
significantly high (OR = 1.59, 95% CI 1.329-1.907, p <
.001) [7]. The association between periodontitis and car-
diovascular disease in meta-analysis literature is stronger
when systemic inflammatory and serologic markers are
used to determine the systemic bacterial exposure sec-
ondary to periodontitis [8].
Several biological mechanisms have been suggested to
explain the association between periodontal infections
and atherosclerosis:
1. Systemic consequences of periodontal infection
(indirect pathway)
Patients with periodontitis have increased levels of
C-reactive protein, fibrinogen, TNF-a,I L - 1 ,I L - 6a n d
other acute phase reactants associated to cardiovascular
events [9,10]. Proinflammatory cytokines (TNF-a,I L - 1 ,
IL-6) reduce the expression of endothelial Nitric Oxide
Synthase (eNOS), [11,12] increase endothelial synthesis
of NADPH oxidase, [13] and promotes the expression of
endothelial cell adhesion molecules (e-Selectin, ICAM-1,
VCAM-1)[14]. It is well-know that the absence of anti-
atherogenic properties in the endothelium augments the
vascular migration of leukocytes (diapedesis) to athero-
sclerotic plaques [4]. In addition, increased activation of
platelets has been reported in subjects with periodontitis
[15]. Despite the evidence, the contribution to other
classic risk factors of CVD of the systemic inflammation
associated with periodontitis remains largely unknown.
2. Invasion of periodontal pathogens into atherosclerotic
plaques (Direct pathway)
Periodontal pathogens (i.e., Porphyromonas gingivalis,
Aggregatibacter actinomycetencomitans, Prevotella inter-
media, Treponema denticola,a n dEikenella corrodens)
have been found in atherosclerotic plaques [16,17].
Recent studies have shown that invasion by P. gingivalis
induces the expression of endothelial cell adhesion
molecules, IL-8, IL-6, MCP-1, and TLR-4 [18-20].
P. gingivalis HSP60 (GroEL) induces TLR-2 and TLR-4
expression on the surface of endothelial cells, [21] sug-
gesting that autoimmune mechanisms secondary to peri-
odontal infections could play a role in the progression
and development of atherosclerosis [22].
Randomized controlled trials (RCTs) are therefore
important to study the impact of periodontal infections
on cardiovascular disease. A growing number of clinical
trials designed to study the effects of periodontal treat-
ment on cardiovascular disease have been published
during the last decade [23-27]. All RCTs evaluating con-
ventional periodontal therapy effects have used different
biomarkers of inflammation and endothelial function as
surrogate outcomes for cardiovascular events, whereas
definitive endpoints such as death, ischemic heart dis-
ease and cerebrovascular accident are not frequently
used. For instance, clinical trials with definitive cardio-
vascular endpoints in periodontitis patients are not
available due to methodological limitations (i.e. larger
sample sizes, or long term follow-up) and/or ethical
aspects concerning the non-treatment of subjects with
periodontitis for long periods of time.
Hence, the use of surrogate biomarkers in RCT evalu-
ating the effects of periodontal treatment in the preven-
tion of cardiovascular disease is justified, because the
otherwise more definitive outcomes such as cardiovascu-
lar events, cardiovascular deaths, and hospitalizations for
cardiovascular complications requires long follow-up
periods. Surrogate biomarkers such as flow-mediated,
endothelium dependent vasodilatation of the brachial
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technique for measuring endothelial function in humans
[28]. FMD is decreased in subjects with cardiovascular
risk factors (i.e. diabetes, hypertension, obesity, and
smoking among others) and atherosclerosis [29].
Furthermore, positive changes in lifestyle (diet, smoking
cessation and physical exercise) as well as cardiovascular
drugs (ACE inhibitors, statins, oral hypoglycemic drugs,
and calcium antagonists) improve endothelial function
in humans [30-32]. The use of FMD as a biomarker for
cardiovascular disease has been recently supported by
studies reporting association between endothelial dys-
function and cardiovascular events [33].
To date, there are some published RCTs that have
found an improvement on endothelial function after
periodontal treatment (REF). However, there are several
reasons to justify the development of more clinical trials
to study this association:
1. Extrapolation of results to the general community
(external validity): Only subjects with chronic severe
generalized periodontitis (less than 1% of the adult
population) have been included in clinical trials of peri-
odontal treatment and endothelial function, [23-27]
therefore there is no available evidence that periodontal
treatment improves endothelial function in subjects
affected by slight or moderate periodontitis, both more
prevalent forms of periodontal disease. Furthermore, the
effects of periodontal treatment on endothelial function
in diverse ethnic/social groups with other co-morbidities
(i.e. obesity, diabetes, cardiovascular disease, metabolic
syndrome, chronic renal failure) are unknown.
2. Differences in periodontal disease treatment strate-
gies: some treatment protocols of periodontal disease
used in some RCTs are not available or affordable in
non-industrialized countries (i.e. local antibiotic therapy
with minocycline microspheres).
3. Methodological limitations of published trials: most
published trials do not include a control group (single
arm clinical trials) and only one RCT published to date
by Tonnetti et al. [25] fully complied with the CON-
SORT statement [34]. Moreover, information regarding
the periodontal diagnosis and disease parameters of the
subjects included in recent clinical trials is frequently
incomplete.
4. Consistency: results are consistent when the asso-
ciation persists despite the use of alternative designs, by
different researchers and different geographic locations.
More RCTs with design improvements and conducted
by different research groups are required to confirm the
beneficial effects of periodontal treatment on biomarkers
of cardiovascular disease.
In summary, current evidence supports a biologically
plausible association between periodontal disease and
atherosclerosis. To date, few studies have evaluated the
effects of periodontal treatment on endothelium-depen-
dent brachial artery flow-mediated dilatation. Moreover,
the evidence obtained from observational studies is still
controversial, probably due to selection biases that have
resulted in weaker association strengths. This RCT will
be conducted to help to confirm a possible association
between periodontitis and cardiovascular disease, to
unveil some biological mechanisms by which periodon-
tal treatment could reduce cardiovascular risk and to
increase the external validity of previous studies.
The study hypothesis is that periodontal treatment
with scaling and root planning supplemented with
chlorhexidine (Full-Mouth Disinfection) - without sys-
temic antibiotics, improves endothelial function and
other biomarkers of cardiovascular disease in subjects
with moderate to severe periodontitis. ClinicalTrials.
gov Identifier: NCT00681564.
Methods/Study Design
Elegibility
- Enrolling of study participants
The periodontal status of potential study participants
will be examined by a single periodontists at recruit-
ment (JQ) who will not be involved in any treatment or
follow-up of research subjects. A physical examination
and structured interview by a certified physician (JR)
will be performed to assess eligibility. A member of the
research team will explain the study protocol and the
informed consent to all the eligible subjects. Inclusion
and exclusion criteria are depicted in Table 1.
Settings
Treatments and tests (blood samples, endothelium-
dependent brachial artery flow-mediated dilatation,
radiographs, subgingival samples and microbial cultures)
of this RCT will be performed at the Universidad del
Valle at Cali, Colombia. Patients will be recruited from
State-funded primary care Health Centers (Cañaveralejo
and Siloe), and Universidad del Valle dental school,
located in the same geographical region of Cali.
Study design
This is a single blind (evaluators of study variables and
outcomes) clinical trial designed to evaluate the effects
of periodontal treatment on endothelium-dependent
brachial artery flow-mediated dilatation in 98 subjects
with moderate to severe periodontitis. Eligible subjects
for the present study will be invited to the following vis-
its (Figure 1):
- Visit I
periodontal clinical parameters, subgingival samples col-
lection (for microbial cultures and Polymerase Chain
Reactions to detect specific periodontal pathogens), peri-
apical radiographs, medical examination, and structured
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Valle).
- Visit II
baseline endothelium-dependent brachial artery flow-
mediated dilatation and anthropometric parameters
(weight, height, and abdominal circumference). A fasting
blood sample will be obtained to determine glucose,
insulin, hs-CRP, lipid profile, and a pro-inflammatory
cytokine panel by Multiplex
®.
- Visit III
randomization to supragingival and subgingival plaque
cleaning and calculus removal, four quadrants in one
session, plus chlorhexidine (treatment group, full-mouth
disinfection protocol) or supragingival plaque removal
(control group, adult prophylaxis). All the interventions
will be performed by two qualified periodontists at the
School of Dentistry (Universidad del Valle), at Cañavera-
lejo Health Center or at Siloe Health Center.
- Visit IV (24 hours after periodontal treatment)
endothelium-dependent brachial artery flow-mediated
dilatation and fasting blood samples at the School of
Basic Sciences (Universidad del Valle).
- Visit V (12 weeks after periodontal treatment)
endothelium-dependent brachial artery flow-mediated
dilatation, periodontal parameters, and subgingival sam-
ples at the School of Basic Sciences at the Universidad
del Valle. A fasting blood sample will be obtained to
determine glucose, insulin, hs-CRP, lipid profile, and
cytokines by Multiplex
®.
- Visit VI
follow-up (intervention group) and treatment (control
group) performed by a periodontist at the School of
Dentistry (Universidad del Valle), Cañaveralejo or Siloe.
Outcomes
- Primary outcome
The primary outcome is the difference on endothelium-
dependent brachial artery flow-mediated dilatation
(FMD) at baseline and three months after randomization
[Time Frame: Baseline, 24 h, and 12 weeks after
treatment].
- Secondary outcomes
Secondary outcomes of this study are hs-CRP and glu-
cose serum levels, blood lipid profile, and HOMA index
[Time Frame: Baseline, 24 h and 12 weeks after
treatment].
Interventions
All procedures in the control and treatment group will
be performed by three certified periodontists following
standard treatment guidelines. Standard Operating
Table 1 Inclusion and exclusion criteria
Inclusion criteria
￿ Male or female
￿ 25 years of age or older
￿ Three or more periodontal pockets with a probing depth (PD) > 5
mm
￿ Have at least 16 natural teeth excluding third molars
￿ Provide informed consent and willingness to cooperate with the
study protocol
Exclusion Criteria
￿ History of antibiotic use in the previous three months
￿ Pregnant or lactating females
￿ Treatment with antihypertensive, antilipemic, antiarrhythmic, and
other cardiovascular drugs
￿ Systemic diseases such as diabetes, HIV/AIDS, liver disease, chronic
renal failure, tuberculosis, and autoimmune diseases
￿ Previous history of cardiovascular disease: Acute myocardial
infarct, stable angina, unstable angina, heart failure, atrial fibrillation,
AV blockade, peripheral vascular disease, and cerebrovascular
accident
￿ Patients who received periodontal treatment within the last 6
months
￿ Patients who require antibiotic prophylaxis before examination or
treatment
￿ Patients with some mental disability
Population
Sample
n=98
Timeline
- Periodontal
  parameters
- Medical 
  examination
- Radiographs
- Subgingival
  microbiology
Visit I Visit II
- Anthropometric 
  parameters
- FMD
- Blood 
  biochemistry
Visit III
R
Treatment 
group 
n=49
Control
 group
n=49
Visit IV
- FMD
- Blood  
  samples
- Periodontal
  parameters
- FMD
- Blood 
  biochemistry
- subgingival
  microbiology
Visit V
Data 
analysis
Study 
Design
Acceptance to 
participate
1-2 w
after enrollment
1-2 w
after Visit I
1 w
after Visit II
24 h
post-intervention
12 w
post-intervention
Figure 1
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zation of the interventions in the control and treatment
groups. To ensure the uniform delivery of the interven-
tions, an experienced periodontist (JS, Director of Peri-
odontology Program at Universidad del Valle) will be
responsible for the training of the team of dental profes-
sionals involved in the delivery of the interventions. In
addition, a videotape of the interventions were obtained
and reviewed to fully comply with the protocol. Patients
randomized to the control group received a conventional
adult prophylaxis (dental cleaning), consisting in one
session of supragingival removal of plaque biofilm with
the use of mechanical scaling and coronal polishing.
Patients randomized to the treatment group will be trea-
ted using the one-stage full-mouth disinfection protocol
consisting in the following procedures:
￿ Administration of local anesthesia [lidocaine (1%)
with epinephrine]
￿ Scaling and root planing with ultrasonic devices and
curettes, four quadrants in one session
￿ Tongue brushing with a 1% chlorhexidine gel
(1 minute)
￿ Mouth rinsing with a 0.2% chlorhexidine solution for
(2 minutes)
￿ Subgingival chlorhexidine (1%) irrigation in all
pockets
￿ Twice daily rinsing with chlorhexidine (1 minute)
during fourteen days after the periodontal intervention
￿ Dental extractions will be performed at the end of
patient follow-up (only in cases of teeth that could not
be preserved)
Sample size
The primary outcome FMD was selected as the critical
variable to calculate the sample size. 49 patients (98 in
total) in each group are required to have an 80% chance
of detecting as significant (at the two sided 5% level) a
1% difference between the two groups in the mean
FMD, with assumed standard deviation of 2.6 and a
planned 15% rate of missing patients on the follow up.
Randomization, allocation concealment and blinding
Subjects will be randomized into one of two groups:
1) treatment group (one stage full-mouth disinfection),
and 2) control group (conventional adult prophylaxis).
Randomization will be stratified on the basis of gender
(male or female), and smoking status (current smokers:
subjects who reported regular smoking of one or more
cigarettes a day for at least one year; non-smokers: never
smoke and former smokers who had stopped smoking
for at least 12 months). The sequence will be generated
using a random number generator in a computer by an
independent researcher not involved in the interventions
or measuring the clinical variables. Random permuted
blocks with a size of four patients will be selected.
Sequentially numbered, opaque, sealed envelopes
(SNOSE) were developed for the implementation of the
random sequence.
On the treatment day, a trained nurse will open the
corresponding numbered envelope at the Cañaveralejo
Health Center or at the dental clinics Universidad del
Valle. The patient’s group allocation will be given to the
periodontist to perform the corresponding intervention.
Due to the nature of the interventions, it is no possible
to blind study participants and periodontists for the
treatment protocol. Outcome evaluators and data ana-
lysts will be blinded to the group assignment. Detailed
instructions on methods to maintain the blind will be
given to the researchers, health care providers and out-
come evaluators. Furthermore, these instructions were
reinforced in bimonthly meetings with the personal
involved in the study and detailed in the operations
manual.
Periodontal examination and subgingival samples
Calibrated dentists with experience in performing peri-
odontal examinations will perform the evaluation of the
periodontal status of recruited patients. The following
clinical parameters will be evaluated:
A. Number of present teeth.
B. Gingival Margin Level (GML): distance in milli-
meters from the cemental-enamel junction (CEJ) to the
gingival margin.
C. Probing Pocket Depth (PD): Distance in millimeters
from the gingival margin to the periodontal pocket as
measured with a calibrated periodontal probe.
D. Clinical Attachment Level (CAL): distance in milli-
meters from the CEJ to the deepest aspect of the period-
ontal sulcus or pocket.
E. Bleeding on Probing (BOP): the presence of BOP
will be expressed as yes/no at each site. The extent of
BOP will be reported as a percentage of all sites.
GML, PD, and CAL will be recorded at six sites per
tooth. PD and CAL will be reported in each patient as
follows:
A. Mean PD
B. Mean CAL
C. Number of sites with PD ≥ 4 and PD ≥ 5
D. Number of sites with CAL ≥ 3 and CAL ≥ 4
The six deepest pockets (>4 mm) on each patient were
selected for subgingival microbial samples. The supra-
gingival plaque will be removed with cotton gauze and a
sterile curette. Subsequently, two absorbent paper points
(#45) are introduced to the bottom of each pocket for a
period of 20 seconds. Six points will be collected in a
sterile Eppendorf tube and stored at - 70°C until analysis
by Polymerase Chain Reaction (PCR). The remaining six
points will be placed into vials containing transport
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colony identification.
Blood samples
Venous blood samples will be withdrawn from the
antecubital vein in fasting conditions (8 to 10 hours).
Blood samples will be collected using three vacutainer
tubes, one dry, one with EDTA and another with
sodium heparin. One 1000 uL aliquote of the EDTA
blood sample will be used for Complete Blood Count
(CBC). All remaining samples will be centrifuged at
1500 rpm during 10 minutes to extract the plasma and
serum. Plasma obtained during visits II, IV and V will
be stored in Eppendorf vials at -70°C until the end of
the study for the analysis of cytokines by Multiplex
®,
hs-CRP and insulin. Serum samples will be immedi-
ately analyzed for measurement of glucose and lipid
profile.
Biochemical markers
Biochemical tests will be performed in the Microbiology
and Immunology Laboratory, from the Universidad del
Valle (Cali, Colombia) and other private certified Clini-
cal Laboratory.
Plasma glucose levels: glucose measurement will be
performed using enzymatic-colorimetric techniques
(Selectra, Merck).
Lipid profile: High-density lipoproteins cholesterol
(HDL-C), total cholesterol (TC) and triglycerides will
be determined by enzymatic-colorimetric techniques
(Selectra, Merck). Low-density lipoproteins choles-
terol (LDL-C) will be calculated using the Friedwald
equation: LDL-C = TC-(HDL-C+TG/2.2).
High sensitivity C-Reactive Protein (hs-CRP): the fast-
ing plasma hs-CRP concentrations will be analyzed
using a solid-phase, chemiluminescent immuno-
metric assay (Immulite 1000, Siemens).
Complete Blood Count (CBC):C B Cw i l lb ep e r -
formed using an automated analyzer (Advia 60,
Siemens).
Luminex multiplex assay for measurement of
cardiovascular risk biomarkers
Cardiovascular risk biomarkers will be determined on
plasma samples using the Luminex-200 system (Lumi-
nex Corporation). This system allows measuring up to
200 proteins simultaneously in a small sample volume
(25-50 μL). MILLIPLEX™ MAP biomarker panel will be
used to determine the following cardiovascular risk bio-
m a r k e r s :M M P - 9 ,M P O ,P A I - 1(total), sE-Selectin,
sICAM-1, sVCAM-1, hs-CRP, fibrinogen, haptoglobine,
amyloid A and amyloid P.
Culture of periodontopathic and superinfecting bacteria
The samples will be analyzed using microbial culture
techniques for the presence of periodontopathic bacteria
according to Slots[35]. Briefly, all samples will be pro-
cessed before 24 hours at room atmosphere (25°C) and
immediately incubated in CO2 and anaerobic culture
systems. Brucella blood agar medium will be incubated
at 35°C in an anaerobic jar for 7 days. The TSBV med-
ium will be incubated in 10% CO2 i na i ra t3 7 ° Cf o r
4 days. Presumptive identification will be performed
according to methods described by Slots & Reynolds
and Slots et al.[36,37] to identify by colony morphology
and Gram stain for Campylobacter spp., Eubacterium
spp., Fusobacterium spp., Capnocytophaga spp., Dialister
pneumosintes. Colony morphology characterized by the
presence of an inner star, and catalase positive test will
be used to identify Aggregatibacter actinomycetemcomi-
tans. In addition, Porphyromonas gingivalis, Prevotella
intermedia/nigrescens, Tannerella forsythia, Micromonas
micros and Eikenella corrodens will be identified by the
use of a commercial micromethod system (RapID ANA
II, Remel, Norcross, GA, USA). Gram-negative enteric
rods will be sub-cultured and colony purified on Mac-
Conkey and Cetrimide agar plates and identified using a
standardized biochemical test (API 20E
®,b i o M e r i e u x ,
Inc, Marcy l’Etoile, France). Total viable counts (TVC)
will be defined as the total number of colony forming
units obtained on non-selective media plates. Species
found on selective media will be enumerated and pre-
sented as percentage (%) and counts × 10
5.F o rt h ei s o -
lation of enteric bacteria, MacConkey agar will be used
and incubated in aerobic atmosphere at 37°C for
24-48 hours. A Gram stain will be performed to
colonies that grew on MacConkey agar medium for veri-
fication. The subgingival presence of Human Cytomega-
lovirus (HCMV) also will be determined at these
samples using a nested PCR technique.
Polymerase chain reaction (PCR)
Bacterial and Viral DNA extraction will be performed
according to Boom et al.[38] Bacterial PCR will be per-
formed as described by Ashimoto et al.[39] in and Saiki
et al.[40] For P. gingivalis, T. forsythia, E. corrodens and
C. rectus a5 0μl of a reaction mixture containing 10.0
μl sample template, 5.0 μl of 10× PCR buffer (50 mM
KCl, 10 mM Tris-HCl [pH 9.0 a 25°C], 1.5 mM MgCl2
and 0.1% of Triton
® X-100) o PROMEGA0.25 U of Taq
DNA polymerase, 5.0 μl (0.2 Mm) of each of deoxyribo-
nucleotides, 1.0 μl( 2μM) of the primer from the bac-
teria being investigated and 3.0 μlM g C l 2 (1.5 mM), was
used. For A. actinomycetemcomitans, P. intermedia y
P. nigrescens the concentration of MgCl2 was 2.25 mM
The primers used will be those recommended by
Ashimoto et al., [39] positive and negative controls will
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weight marker. The sample will be replaced by 10.0 μl
sterile distilled water in the negative control and 10.0 μl
of DNA from the bacteria being investigated will be
included in the positive control.
Samples will be amplified in a thermal cycler (MyCy-
cler™ Termal Cycler, Bio-Rad). The PCR temperature
profile for P. gingivalis, T. forsythia, E. corrodens and
C. rectus included an initial denaturation step at 95°C
for 2 min followed by 36 cycles of: denaturation step at
95°C for 30 s, a primer annealing step at 60°C for
1 min, an extension step at 72°C for 1 min and a final
step of 72°C for 2 min. The temperature profile for
A. actinomycetemcomitans, P. intermedia y P. nigrescens
will included an initial step of 95°C for 2 min followed
by 36 cycles of: 94°C for 30 s, 55°C for 1 min, 72°C for
2 min and a final step of 72°C for 10 min.
P. gingivalis ATCC 33277, C. rectus ATCC 33238,
T. forsythia ATCC 43037, E. corrodens ATCC 23834,
A. actinomycetemcomitans ATCC 29522, P. intermedia
ATCC 25611 y P. nigrescens ATCC 33563 reference
strains will be used. P. gingivalis will be identified by the
presence of an amplified product in the 404 base pair
(bp) band, C. rectus by an amplified product in the 598
bp band, T. forsythia in the 641 bp band, E. corrodens in
the 688 bp band, P. intermedia in the 575 bp band and
P. nigrescens in the 804 bp band. The primers used will
be the ones described by Ashimoto et al. [39] were
selected with the help of the Ribosomal database Project
(RDP) program.
A nested PCR for HCMV will be used to determine
the subgingival viral presence. HCMV PCR conditions
and primers will be selected as published by Parra et al.
[41] Positive control - DNA extracted from HCMV
Towne strain and negative control will be used during
the experiments. A band of 123 base pair will represent
a HCMV positive isolation.
Bacterial and viral PCR products will be electrophore-
tically fractioned at 4 V/cm in 1.5% agarose gel in TAE
buffer (Tris acetate-EDTA) stained with cyber green and
visualised on a transilluminator under 300 nm ultravio-
let light.
The subgingival microbiota composition of the
patients will be determined at baseline and at three
months after study inclusion and will be analyzed as
other independent microbial risk factor. The effect of
periodontal treatment on subgingival microbiota compo-
sition will be also determined.
Physical and anthropometric measurements
All physical and anthropometric measurements will be per-
formed in the morning before breakfast. Participants will
be wearing light clothes and no shoes during examination.
Weight: The weight scale will be placed in a hard-flat
surface and properly calibrated before each measure-
ment. All measurements will be taken with the
patient standing without support on the centre of
the scale with their weight distributed evenly in both
foot.
Height: will be measured using a metric tape with
the patient standing against the wall with their head
in the Frankfort plane.
Body Mass Index (BMI): will be calculated using the
weight (kg) divided by the second power of the
height (meters).
Waist: the circumference of the abdomen at its nar-
rowest point will be measured using a metric tape
against the skin of the participants. All measure-
ments will be taken perpendicular to the long axis of
the trunk, between the lower costal border and the
top of the iliac crest.
Heart rate: calculated using the R-R interval in the
electrocardiogram with the patient in the supine
position after a 5-minute rest.
Blood pressure (BP): BP will be taken using a mercury
sphygmomanometer on the right arm, with the
patient comfortably seated, after a 5-minute rest [42].
Assessment of vascular function
All the assessments of vascular function will be per-
formed in the morning, in a temperature controlled
room, with participants required to fast for at least
8 hours. Flow-mediated, endothelium dependent vasodi-
latation of the brachial artery (FMD) will be measured
by the technique described by Celermajer et al. [28]
using the guidelines reported by Coretti et al. [43] The
ultrasound image of the right brachial artery will be
measured longitudinally 5-10 cm above the antecubital
fossa by a 2D high-resolution (Siemens SG-60, USA)
ultrasound device, using a 7.5 MHz linear array transdu-
cer. Ultrasound procedures will be executed with the
subject resting quietly in supine position for at least 10
minutes. All measurements will be taken at end-diastole
guided by the electrocardiogram. The baseline diameter
of the brachial artery will be measured from the anterior
to the posterior intima/lumen interface at three points
located at a predetermined distance, the mean diameter
of the brachial artery will be calculated as the average of
the three measures. After the baseline measurement, a
pneumatic tourniquet positioned around the right arm
will be inflated to at least 50 mm Hg above the systolic
pressure for at least five minutes. A rapid release of the
cuff will induce reactive hyperemia and shear stress on
the endothelium, leading to endothelium-dependent
v a s o d i l a t a t i o n ,m a i n l yd u et ot h ei n c r e a s eo ff r e e
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2+ concentration with subsequent activation
of endothelial Nitric Oxide Synthase (eNOS) and release
of NO to the vascular smooth muscle[43]. FMD will be
calculated as the percentage of change in the diameter
of brachial artery measured 45-60 s after cuff release in
relation to the baseline measure (FMD%). After
10 minutes of rest, sublingual administration of 25 μgo f
nitroglycerin will be used to measure the endothelium-
independent vasodilatation.
Statistical analysis
All statistical analyses will be performed using the inten-
tion-to-treat principle unless stated otherwise. A P of
0.05 will be used as a cutoff for statistical significance.
The primary outcome (difference on endothelium-
dependent brachial artery FMD at baseline and three
months after randomization) and the secondary out-
come (hs-CRP, glucose, blood lipid profile, and HOMA
index) will be analyzed using repeated measures
ANOVA for continuous variables. Differences in propor-
tions in outcomes between the treated group and the
control group will tested for statistical significance by
c2-test or Fisher exact test if applicable.
Study conduct and monitoring
This study will be conducted in accordance with
accepted ethical and scientific standards (SOP) in order
to protect participants, to preserve the study’s scientific
integrity and to identify problems and correct them effi-
ciently. This study will also be monitored by the Human
Rights Committee at the Universidad del Valle Institu-
tional Review Board composed of experts in medicine,
dentistry and clinical epidemiology. Monitoring reports
will be submitted to the committee focusing on infor-
mation about patient compliance, protocol adherence,
data retrieval, and adverse events to the intervention. All
adverse events will also be reported to the Universidad
del Valle IRB. The Principal Investigators’ monitoring
will detect consent irregularities, unsafe confidentiality
practices, and participants who are ineligible because of
errors in assessing or recording relevant medical condi-
tions in an effort to decrease adverse events. In addition,
there will be weekly conference calls between the coor-
dinating Center and researches to review procedures
and address potential problems. The Coordinating Cen-
ter will also ensure the quality and integrity of the data
collection process.
Ethical aspects
This clinical trial will be conducted in accordance with
the Good Clinical Practice Guidelines, the Helsinki’s
Declaration, and the Colombian legislation as per the
Resolution 8430 of 1993 from the Ministry of Health.
Prior to de admission to the patients in the study, the
objectives and the methodology will be explained and
the patient will provide written informed consent in a
form designed for such purpose. Confidentiality of the
patients will be maintained in all the phases of the
study. The patients may refuse to continue participating
if they no longer wish to continue the study. The design
and methods of this RCT are in accordance with the
recently published extension of the CONSORT state-
ment to randomized trials of non-pharmacological
treatment [44].
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